Open Nav

Neurotez Inc.

To attract investors and/or partners

  • Date:Wednesday, October 17
  • Time:4:00 PM - 4:15 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Our mission is to become world leaders in biotechnology, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs that are both safe and efficacious. We are dedicated to excellence, improving lives and serving the public responsibly.
  • Company
  • Company HQ City:Bridgewater
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • CEO/Top Company Official:Nikolaos Tezapsidis
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :Memtin (Leptin) for Alzheimer's disease
  • Development Phase of Primary Product:Other/Not Applicable
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk. Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain. This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels. The administration of Leptin inhibits both the production of amyloid beta (Aβ) and also the phosphorylation of tau protein in a variety of in vitro and in vivo systems.
  • Total Amount Raised to Date, In All Rounds:$5million